The Australian Medical Association Limited and state AMA entities comply with the Privacy Act 1988. Please refer to the AMA Privacy Policy to understand our commitment to you and information on how we store and protect your data.

×

Search

×

New PBS and ARTG listings

Australians living with non-small cell lung cancer and early stage acute lymphoblastic leukaemia will be able to access better treatment options with new listings on the Pharmaceutical Benefits Scheme (PBS).

29 Nov 2019

Australians living with non-small cell lung cancer and early stage acute lymphoblastic leukaemia will be able to access better treatment options with new listings on the Pharmaceutical Benefits Scheme (PBS).

More than 2,200 patients with metastatic non-small cell lung cancer will now be able to access Keytruda® (pembrolizumab) as a first line treatment in combination with chemotherapy.

“This means most patients will not have to fail treatment with chemotherapy before accessing this game changing treatment for this condition,” Health Minister Greg Hunt said.

“Patients may have otherwise paid up to $120,000 a year depending on their specific cancer subtype.”

The existing listing of leukaemia medicine Blincyto® (blinatumomab) has also been extended from December.

Blincyto® will now be available for the treatment of patients in the early stage of acute lymphoblastic leukaemia, but have minimal residual disease (MRD).

A patient has MRD if they respond well to initial chemotherapy but a small number of cancer cells can still be detected.

“Without PBS subsidy, approximately 86 patients would pay up to $150,000 for each course of treatment,” the Minister said.

 

*******************************************************************************************************************************

 

AJOVY® (fremanezumab), is now listed on the Australian Register of Therapeutic Goods (ARTG) for the prevention of migraine in adults.

It is the first and only treatment in its class with two dosing options, with quarterly (675mg) and monthly (225mg) dosing available.

The ARTG listing is based on results from a pivotal double-blind, randomised, Phase III clinical trial of adult patients with chronic migraine that showed a significant benefit of the drug over placebo in reducing the number of headache and migraine days per month.

This product is not listed on the PBS.

 

 


Published: 29 Nov 2019